Ad
related to: fda orphan drug
Search results
Mabwell Announces 9MW2821 Clinical Data and Latest Progress to be presented at 2024 ASCO Annual...
FOX 59 Indianapolis· 2 days agoMabwell (688062.SH), an innovation-driven biopharmaceutical company, announced the data and latest...
BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From...
FOX 59 Indianapolis· 6 days agoThe Company will share the data with an international audience of patient advocacy groups, physicians, research organizations, industry representatives, key thought leaders and decision makers ...
Transcenta Debuts Encouraging Phase II Data from First-line Triple Combo Trial of Osemitamab...
NBC 10 - FOX 14 Monroe· 3 days agoPhase II results reveal median PFS of 12.6 months in patients with CLDN18.2 high or medium expression, including in patients with PD-L1 CPS<5. PRINCETON, N.J. and SUZHOU, China, May 23, 2024 ...
Gilead (GILD) Announces Positive Interim Results on PBC Drug
Zacks via Yahoo Finance· 6 days agoGilead Sciences (GILD) experimental candidate, seladelpar, demonstrates significant improvements in...
Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent...
FOX21 Colorado Springs· 3 days agoPrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the Company ...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 3 days agoThe study is examining the safety and tolerability of SPN-817 as adjunctive therapy in adult patients with treatment-resistant seizures, as well as finding effective doses in various treatment-resistant ...
Health Brief - The Washington Post
Washington Post· 6 days agoAnalysisBiden, Trump and the science of aging brainsThe Washington Post’s essential guide to health policy news.By Joel Achenbach and McKenzie BeardMay 20, 2024The Health 202AnalysisMarkey targets ...
Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement - Kazia...
Benzinga· 3 days agoKazia Therapeutics Limited KZIA (Kazia or the company) received a letter on May 22, 2024 from Nasdaq notifying the Company that, while the Company has not regained compliance with the Minimum ...
Medicenna to Present Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming Sachs 10th Annual...
Digital Journal· 4 days agoMedicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced today that it ...
Gilead (GILD) Announces Positive Interim Results on PBC Drug
Zacks· 6 days agoGilead Sciences (GILD) experimental candidate, seladelpar, demonstrates significant improvements in liver disease progression and reduced itching in primary biliary cholangitis study.
